ERBB2 and breast cancer: Thus, the difference in distribution between HR-HER2-positive and HR + HER2-positive disease may be one reason why the pCR rate was significantly lower in HR + HER2-positive (especially in triple positive) than HR-HER2-positive breast cancer patients.